SCHEMBL176416

SCHEMBL176416

CCO[Si](CCCOC(=O)CCC(=O)O)(OCC)OCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.38
GSTP1 P09211 1/20 0.38
GSTM2 P28161 1/20 0.38
DGKA P23743 1/20 0.38
ADRA2A P08913 1/20 0.36
ADRA1A P35348 1/20 0.36
MAPT P10636 1/20 0.35
BLM P54132 1/20 0.35
KDM6B O15054 1/20 0.35
KDM5C P41229 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
PHF8 Q9UPP1 1/20 0.35
KDM2A Q9Y2K7 1/20 0.35
PAM P19021 2/20 0.35
NPC1 O15118 1/20 0.35
NAAA Q02083 1/20 0.34
CYP1A2 P05177 1/20 0.34
LMNA P02545 1/20 0.33
DNM1 Q05193 1/20 0.33
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL176417 0.93 DGKA (0.42) HTR2CDGKAADRA2AADRA1AMAPT
SCHEMBL29028494 0.86 HTR2C (0.47) HTR2CDGKAADRA2AADRA1AMAPT
SCHEMBL6267406 0.86 DGKA (0.44) HTR2CDGKAADRA2AADRA1AMAPT
SCHEMBL28289669 0.86 HTR2C (0.47) HTR2CDGKAADRA2AADRA1AMAPT
SCHEMBL767599 0.85 HTR2C (0.37) HTR2CDGKAADRA2AADRA1AMAPT
SCHEMBL27841157 0.85 LTA4H (0.39) HTR2CGSTP1GSTM2DGKAADRA2A
SCHEMBL8839165 0.85 DGKA (0.52) HTR2CDGKAMAPTPAMNAAA
SCHEMBL9323709 0.85 GAA (0.38) DGKAMAPTEGLN1NAAALMNA
SCHEMBL12080684 0.83 DGKA (0.38) HTR2CDGKAADRA2AADRA1AMAPT
SCHEMBL10277563 0.83 TSHR (0.38) HTR2CGSTP1GSTM2DGKAADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121015962-A Antibacterial anti-inflammatory regenerated marrow covering material and preparation method thereof 广西医科大学 2025-11-28 CN disclosed
CN-105165823-A Enhanced Retention Capabilities Through Methods Comprising Surface Treatment Of Functional Particulate Carrier Materials, And Functional Particulate Carrier Materials Made Therefrom WORLD MINERALS INC 2015-12-23 CN disclosed
US-8551332-B2 Affinity particle and affinity separation method SHISEIDO COMPANY, LTD. (JP) 2013-10-08 US disclosed
EP-1759761-B1 AFFINITY PARTICLE AND AFFINITY SEPARATION METHOD SHISEIDO CO LTD (JP) 2011-07-27 EP disclosed
EP-1750127-B1 Method of affinity separation. SHISEIDO CO LTD (JP) 2011-07-20 EP disclosed
US-20100137133-A1 Affinity Particle And Affinity Separation Method SHISEIDO COMPANY, LTD. (JP) 2010-06-03 US disclosed
US-20090321358-A1 Affinity Particle And Method Of Affinity Separation SHISEIDO COMPANY, LTD. (JP) 2009-12-31 US disclosed
US-20090321357-A1 Affinity Particle And Affinity Separation Method SHISEIDO COMPANY, LTD. (JP) 2009-12-31 US disclosed
US-20070241054-A1 Affinity Particle And Method Of Affinity Separation SHISEIDO COMPANY, LTD. (JP) 2007-10-18 US disclosed
US-20070181503-A1 Affinity particle and affinity separation method SHISEIDO COMPANY, LTD. (JP) 2007-08-09 US disclosed
EP-1759761-A1 AFFINITY PARTICLE AND AFFINITY SEPARATION METHOD SHISEIDO COMPANY, LTD. (JP) 2007-03-07 EP disclosed
EP-1750127-A1 AFFINITY PARTICLE AND METHOD OF AFFINITY SEPARATION Shiseido Company, Limited (JP) 2007-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090321357-A1 Affinity Particle And Affinity Separation Method FCGR1A, ACP1, FCGR3B HTR2C 3792/4885GSTP1 658/4885GSTM2 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.